Imagion Biosystems has lodged the announcement “Pro-Rata Non-Renounceable Rights Issue” with the Australian Securities Exchange.
View the announcement “Pro-Rata Non-Renounceable Rights Issue.”
Imagion Biosystems Delivers Major Milestone — IND Application Lodged with U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent
January 31, 2026
Imagion Biosystems Hits Major Milestone, Submits IND Application to U.S. FDA for Phase 2 Trial of MagSense® HER2 Imaging Agent Key Highlights: Imagion Biosystems has